These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19541813)

  • 1. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
    Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis.
    Pelusi S; Girelli D; Rametta R; Campostrini N; Alfieri C; Traglia M; Dongiovanni P; Como G; Toniolo D; Camaschella C; Messa P; Fargion S; Valenti L
    BMC Nephrol; 2013 Feb; 14():48. PubMed ID: 23433094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
    van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
    PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease.
    Valenti L; Swinkels DW; Burdick L; Dongiovanni P; Tjalsma H; Motta BM; Bertelli C; Fatta E; Bignamini D; Rametta R; Fargion S; Fracanzani AL
    Nutr Metab Cardiovasc Dis; 2011 Aug; 21(8):568-75. PubMed ID: 20392616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis.
    Sangwaiya A; Manglam V; Busbridge M; Thursz M; Arnold J
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):721-4. PubMed ID: 21654321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
    Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
    Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.
    Nelson JE; Brunt EM; Kowdley KV;
    Hepatology; 2012 Nov; 56(5):1730-40. PubMed ID: 22611049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels.
    van Dijk BA; Laarakkers CM; Klaver SM; Jacobs EM; van Tits LJ; Janssen MC; Swinkels DW
    Br J Haematol; 2008 Sep; 142(6):979-85. PubMed ID: 18557745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis.
    Girelli D; Trombini P; Busti F; Campostrini N; Sandri M; Pelucchi S; Westerman M; Ganz T; Nemeth E; Piperno A; Camaschella C
    Haematologica; 2011 Apr; 96(4):500-6. PubMed ID: 21173098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations.
    Traglia M; Girelli D; Biino G; Campostrini N; Corbella M; Sala C; Masciullo C; Viganò F; Buetti I; Pistis G; Cocca M; Camaschella C; Toniolo D
    J Med Genet; 2011 Sep; 48(9):629-34. PubMed ID: 21785125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
    Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
    Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemochromatosis (HFE) gene mutations in Brazilian chronic hemodialysis patients.
    Perícole FV; Alves MA; Saad ST; Costa FF
    Braz J Med Biol Res; 2005 Sep; 38(9):1321-4. PubMed ID: 16138214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System.
    Tomosugi N; Kawabata H; Wakatabe R; Higuchi M; Yamaya H; Umehara H; Ishikawa I
    Blood; 2006 Aug; 108(4):1381-7. PubMed ID: 16621968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
    Sany D; Elsawy AE; Elshahawy Y
    Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):967-73. PubMed ID: 25193892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre.
    Ryan E; Ryan JD; Russell J; Coughlan B; Tjalsma H; Swinkels DW; Stewart S; Crowe JP
    Acta Haematol; 2015; 133(2):155-61. PubMed ID: 25277871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis.
    Valenti L; Pulixi EA; Arosio P; Cremonesi L; Biasiotto G; Dongiovanni P; Maggioni M; Fargion S; Fracanzani AL
    Haematologica; 2007 Aug; 92(8):1037-42. PubMed ID: 17640859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
    Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
    Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis.
    Brown MC; Gaffney D; Gemmell C; Oakes E; Morris S; Spooner R; Jardine AG; Geddes CC
    Hemodial Int; 2009 Oct; 13(4):460-6. PubMed ID: 19732172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients.
    Valenti L; Valenti G; Como G; Burdick L; Santorelli G; Dongiovanni P; Rametta R; Bamonti F; Novembrino C; Fracanzani AL; Messa PG; Fargion S
    Am J Nephrol; 2007; 27(1):101-7. PubMed ID: 17299255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.